{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:05:47Z","timestamp":1757617547159,"version":"3.44.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04413-5","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:05:06Z","timestamp":1740132306000},"page":"2463-2473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10\u00a0years"],"prefix":"10.1007","volume":"57","author":[{"given":"Haobo","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoze","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"3","key":"4413_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"4413_CR2","doi-asserted-by":"publisher","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K et al (2023) Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol 13:1170124","journal-title":"Front Oncol"},{"key":"4413_CR3","first-page":"CD006885","volume":"5","author":"PF Shang","year":"2011","unstructured":"Shang PF et al (2011) Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 5:CD006885","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4413_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m PU et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"4","key":"4413_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","volume":"109","author":"MD Shelley","year":"2012","unstructured":"Shelley MD et al (2012) Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int 109(4):496\u2013505","journal-title":"BJU Int"},{"issue":"6","key":"4413_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P et al (2024) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)-a summary of the 2024 guidelines update. Eur Urol 86(6):531\u2013549","journal-title":"Eur Urol"},{"issue":"4","key":"4413_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196(4):1021\u20131029","journal-title":"J Urol"},{"issue":"4","key":"4413_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.vaccine.2017.12.010","volume":"36","author":"T Cernuschi","year":"2018","unstructured":"Cernuschi T et al (2018) Bacillus Calmette-Gu\u00e9rin (BCG) vaccine: a global assessment of demand and supply balance. Vaccine 36(4):498\u2013506","journal-title":"Vaccine"},{"issue":"1","key":"4413_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000520630","volume":"107","author":"M Zazzara","year":"2023","unstructured":"Zazzara M et al (2023) Electromotive drug administration of mitomycin C (EMDA\/MMC) versus intravesical immunotherapy with bacillus calmette-gu\u00e9rin (BCG) in Intermediate and high risk non muscle invasive bladder cancer. Urol Int 107(1):64\u201371","journal-title":"Urol Int"},{"issue":"2","key":"4413_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/ijms25020960","volume":"25","author":"M Kochergin","year":"2024","unstructured":"Kochergin M et al (2024) Photodynamic therapy: current trends and potential future role in the treatment of bladder cancer. Int J Mol Sci 25(2):960","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4413_CR11","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1007\/s00345-023-04332-z","volume":"41","author":"G Pignot","year":"2023","unstructured":"Pignot G et al (2023) Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure. World J Urol 41(11):3195\u20133203","journal-title":"World J Urol"},{"key":"4413_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.urology.2024.06.035","volume":"193","author":"HN Abou","year":"2024","unstructured":"Abou HN et al (2024) Does ta low-grade urothelial carcinoma of the bladder with focal high-grade features carry worse prognosis? The Roswell park comprehensive cancer center experience. Urology 193:136\u2013142","journal-title":"Urology"},{"issue":"4","key":"4413_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4274\/MMJ.galenos.2021.48447","volume":"36","author":"M Culpan","year":"2021","unstructured":"Culpan M et al (2021) The clinical impact of tumor grade heterogeneity in non-muscle-invasive urothelial carcinoma of the bladder. Medeni Med J 36(4):310\u2013317","journal-title":"Medeni Med J"},{"issue":"1","key":"4413_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/PAS.0000000000002077","volume":"48","author":"GP Paner","year":"2024","unstructured":"Paner GP et al (2024) International society of urological pathology (ISUP) consensus conference on current issues in bladder cancer. Working group 2: grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and non-urothelial carcinomas. Am J Surg Pathol 48(1):11\u201323","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 4","key":"4413_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","volume":"54","author":"GN Hortob\u00e1gyi","year":"1997","unstructured":"Hortob\u00e1gyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54(Suppl 4):1\u20137","journal-title":"Drugs"},{"issue":"9","key":"4413_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/14740338.2024.2374921","volume":"23","author":"Y Peng","year":"2024","unstructured":"Peng Y et al (2024) Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database. Expert Opin Drug Saf 23(9):1207\u20131214","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"4413_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","volume":"197","author":"R Chou","year":"2017","unstructured":"Chou R et al (2017) Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 197(5):1189\u20131199","journal-title":"J Urol"},{"issue":"6","key":"4413_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.urpr.2014.12.008","volume":"2","author":"J Cusano","year":"2015","unstructured":"Cusano J et al (2015) Process improvements positively impact the use of intravesical mitomycin C after transurethral resection of nonmuscle invasive bladder cancer in a large urban urology practice. Urol Pract 2(6):291\u2013297","journal-title":"Urol Pract"},{"issue":"13","key":"4413_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102699","volume":"34","author":"CC Abou","year":"2024","unstructured":"Abou CC et al (2024) Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC. Fr J Urol 34(13):102699","journal-title":"Fr J Urol"},{"issue":"15","key":"4413_CR20","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMp1615697","volume":"376","author":"BJ Davies","year":"2017","unstructured":"Davies BJ, Hwang TJ, Kesselheim AS (2017) Ensuring access to injectable generic drugs - the case of intravesical BCG for bladder cancer. N Engl J Med 376(15):1401\u20131403","journal-title":"N Engl J Med"},{"issue":"21","key":"4413_CR21","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1002\/cam4.3513","volume":"9","author":"JL Lu","year":"2020","unstructured":"Lu JL et al (2020) Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Cancer Med 9(21):7800\u20137809","journal-title":"Cancer Med"},{"issue":"13","key":"4413_CR22","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.3390\/jcm13133789","volume":"13","author":"S Chiujdea","year":"2024","unstructured":"Chiujdea S et al (2024) Epirubicin and non-muscle invasive bladder cancer treatment: a systematic review. J Clin Med 13(13):3789","journal-title":"J Clin Med"},{"key":"4413_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686918","author":"N Shinohara","year":"1994","unstructured":"Shinohara N et al (1994) Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer the hokkaido university bladder cancer collaborative group. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/BF00686918","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"4413_CR24","first-page":"3422","volume":"123","author":"SY Chen","year":"2010","unstructured":"Chen SY, Du LD, Zhang YH (2010) Pilot study of intravesical instillation of two new generation anthracycline antibiotics in prevention of superficial bladder cancer recurrence. Chin Med J Engl 123(23):3422\u20133426","journal-title":"Chin Med J Engl"},{"issue":"Suppl 5","key":"4413_CR25","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E et al (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):v7-12","journal-title":"Ann Oncol"},{"issue":"1","key":"4413_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12894-019-0530-0","volume":"19","author":"TW Wang","year":"2019","unstructured":"Wang TW et al (2019) Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence. BMC Urol 19(1):90","journal-title":"BMC Urol"},{"issue":"11","key":"4413_CR27","doi-asserted-by":"publisher","first-page":"8945","DOI":"10.1007\/s00432-023-04739-6","volume":"149","author":"L Wang","year":"2023","unstructured":"Wang L et al (2023) The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer. J Cancer Res Clin Oncol 149(11):8945\u20138949","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"4413_CR28","first-page":"33","volume":"18","author":"CA Garneau","year":"2024","unstructured":"Garneau CA et al (2024) Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC. Can Urol Assoc J 18(2):33\u201340","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"4413_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1464-410X.1989.tb05159.x","volume":"63","author":"AA Giesbers","year":"1989","unstructured":"Giesbers AA, Van Helsdingen PJ, Kramer AE (1989) Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. Br J Urol 63(2):176\u2013179","journal-title":"Br J Urol"},{"issue":"5","key":"4413_CR30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"M Kuroda","year":"2004","unstructured":"Kuroda M et al (2004) Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer\u2013The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg\/40ml, 30mg\/40ml, 40mg\/40ml. Eur Urol 45(5):600\u2013605","journal-title":"Eur Urol"},{"issue":"7\u20138","key":"4413_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000500204","volume":"42","author":"Z Mao","year":"2019","unstructured":"Mao Z et al (2019) Comparisons of cardiotoxicity and efficacy of anthracycline-based therapies in breast cancer: a network meta-analysis of randomized clinical trials. Oncol Res Treat 42(7\u20138):405\u2013413","journal-title":"Oncol Res Treat"},{"issue":"7","key":"4413_CR32","first-page":"905","volume":"23","author":"T Saika","year":"1996","unstructured":"Saika T et al (1996) Relationship of intracellular concentration and duration of contamination of pirarubicin and adriamycin in human bladder cancer cell lines and human bladder normal mucosa cell line. Gan To Kagaku Ryoho 23(7):905\u2013909","journal-title":"Gan To Kagaku Ryoho"},{"issue":"7","key":"4413_CR33","first-page":"1206","volume":"84","author":"T Saika","year":"1993","unstructured":"Saika T et al (1993) Tissue concentration of intravesically instilled (2\"R)-4\u2019-o-tetrahydropyranyl-adriamycin or adriamycin in superficial bladder cancer. Nihon Hinyokika Gakkai Zasshi 84(7):1206\u20131210","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"issue":"3","key":"4413_CR34","first-page":"379","volume":"38","author":"J Kawamura","year":"1992","unstructured":"Kawamura J et al (1992) A randomized study of pirarubicin (THP) versus adriamycin (ADM) for intravesical instillation therapy against superficial bladder cancer. Hinyokika Kiyo 38(3):379\u2013385","journal-title":"Hinyokika Kiyo"},{"issue":"12","key":"4413_CR35","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1002\/ijc.31597","volume":"143","author":"S Teleka","year":"2018","unstructured":"Teleka S et al (2018) Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: a prospective pooled cohort study of 800,000 men and women. Int J Cancer 143(12):3071\u20133082","journal-title":"Int J Cancer"},{"issue":"3","key":"4413_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229384","volume":"15","author":"J Evers","year":"2020","unstructured":"Evers J et al (2020) No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. PLoS ONE 15(3):e0229384","journal-title":"PLoS ONE"},{"issue":"5","key":"4413_CR37","first-page":"385","volume":"33","author":"M Cao","year":"2011","unstructured":"Cao M et al (2011) Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer. Zhonghua Zhong Liu Za Zhi 33(5):385\u2013387","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"4413_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12894-024-01410-1","volume":"24","author":"S Chen","year":"2024","unstructured":"Chen S et al (2024) Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study. BMC Urol 24(1):25","journal-title":"BMC Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04413-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04413-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04413-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:15:56Z","timestamp":1757139356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04413-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4413"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04413-5","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}